Related references
Note: Only part of the references are listed.Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
Tomohiro Nishina et al.
INVESTIGATIONAL NEW DRUGS (2018)
Optogenetically controlled protein kinases for regulation of cellular signaling
Anna V. Leopold et al.
CHEMICAL SOCIETY REVIEWS (2018)
YC-1 Inhibits VEGF and Inflammatory Mediators Expression on Experimental Central Retinal Vein Occlusion in Rhesus Monkey
Zhipeng Yan et al.
CURRENT EYE RESEARCH (2018)
The FDA approved PI3K inhibitor GDC-0941 enhances invitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma
Michael Ehrhardt et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer
K. L. Thu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway
Xiangdong Tian et al.
CELL DEATH & DISEASE (2018)
Development of 2-arylbenzo[h]quinolone analogs as selective CYP1B1 inhibitors
Jinyun Dong et al.
RSC ADVANCES (2018)
Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro
Wenwen Gu et al.
CELL BIOLOGY AND TOXICOLOGY (2017)
Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer
Johannes Braegelmann et al.
CLINICAL CANCER RESEARCH (2017)
Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors
Ying Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
New imidoyl-indazole platinum (II) complexes as potential anticancer agents: Synthesis, evaluation of cytotoxicity, cell death and experimental-theoretical DNA interaction studies
Alan R. Cabrera et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2017)
Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer
Wei Zhu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor
Stefano Tomassi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Synthesis and Biological Evaluation of 2H-Indazole Derivatives: Towards Antimicrobial and Anti-Inflammatory Dual Agents
Jaime Perez-Villanueva et al.
MOLECULES (2017)
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
Michael Michael et al.
TARGETED ONCOLOGY (2017)
Identification of an Indazole-Based Pharmacophore for the Inhibition of FGFR Kinases Using Fragment-Led de Novo Design
Lewis D. Turner et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors
Ting Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Rational drug design of indazole-based diarylurea derivatives as anticancer agents
Yan-yan Chu et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2017)
cis-Tetrachlorido-bis(indazole)osmium(IV) and its osmium(III) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339
Gabriel E. Buchel et al.
DALTON TRANSACTIONS (2017)
Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors
Jing Cui et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten et al.
CLINICAL CANCER RESEARCH (2016)
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
Meghan Shea et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)
4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase
Emily J. Hanan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Discovery and structure activity relationship study of novel indazole amide inhibitors for extracellular signal-regulated kinase1/2 (ERK1/2)
Lei Li et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation
Waqar Aman et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore
Kai Schiemann et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Design and optimization of (3-aryl-1H-indazol-6-yl) spiro [cyclopropane-1,3′-indolin]-2′-ones as potent PLK4 inhibitors with oral antitumor efficacy
Sze-Wan Li et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Flavonoids and Naphthoflavonoids: Wider Roles in the Modulation of Cytochrome P450 Family1 Enzymes
Jinyun Dong et al.
CHEMMEDCHEM (2016)
Ruthenium Carbonyl Complexes with Azole Heterocycles - Synthesis, X-ray Diffraction Structures, DFT Calculations, Solution Behavior, and Antiproliferative Activity
Paul-Steffen Kuhn et al.
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY (2016)
Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design
Chun-Feng Chang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity
Stephanie W. Chang et al.
INORGANIC CHEMISTRY (2016)
Discovery of 3-(5′-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation
Wei Yan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19
Aurelie Mallinger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors
Zhen Zhang et al.
MOLECULES (2016)
Design, synthesis and biological evaluation of indazole-pyrimidine based derivatives as anticancer agents with anti-angiogenic and antiproliferative activities
Nevine M. Y. Elsayed et al.
MEDCHEMCOMM (2016)
Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives as Potent and Selective FGFR Kinase Inhibitors
Bin Zhao et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in- human, open-label, dose-escalation phase I study with expansion cohort
Howard A. Burris et al.
ESMO OPEN (2016)
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft
Steven P. Govek et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors
Hui-Ling Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
Teresa Helsten et al.
CANCER AND METASTASIS REVIEWS (2015)
Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential
P. -S. Kuhn et al.
DALTON TRANSACTIONS (2015)
Synthesis of indazole motifs and their medicinal importance: An overview
Digambar D. Gaikwad et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen
Aurelie Mallinger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach
Julian Engel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents
Yong Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
Andiliy Lai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease
Trevor Dale et al.
NATURE CHEMICAL BIOLOGY (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold
Jian Liu et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2015)
Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines
Sundeep Dugar et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Novel potent HIF-1 inhibitors for the prevention of tumor metastasis: discovery and optimization of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives
Rong Sheng et al.
RSC ADVANCES (2015)
Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
Helena A. Yu et al.
JAMA ONCOLOGY (2015)
The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1R,2S)-2-(3((E)-4-(((cis)-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent
Peter B. Sampson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3′[3H]indol]-2′(1′H)-ones as Orally Bioavailable Antitumor Agents
Peter B. Sampson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Overexpression of Mps1 in colon cancer cells attenuates the spindle assembly checkpoint and increases aneuploidy
Youguo Ling et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides
Radoslaw Laufer et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents
Haofei Qi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells
B. P. Kaistha et al.
BRITISH JOURNAL OF CANCER (2014)
Design, Synthesis and Biological Evaluation of Pazopanib Derivatives as Antitumor Agents
Yuping Jia et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2014)
Development of anticancer agents: wizardry with osmium
Muhammad Hanif et al.
DRUG DISCOVERY TODAY (2014)
Osmium(III) Analogues of KP1019: Electrochemical and Chemical Synthesis, Spectroscopic Characterization, X-ray Crystallography, Hydrolytic Stability, and Antiproliferative Activity
Paul-Steffen Kuhn et al.
INORGANIC CHEMISTRY (2014)
The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
Yoshito Nakanishi et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Synthesis of substituted 4-(1H-indo1-6-y1)-1H-indazoles as potential PDK1 inhibitors
Martin Brzozowski et al.
TETRAHEDRON (2014)
Discovery of a new HIV-1 inhibitor scaffold and synthesis of potential prodrugs of indazoles
Se-Ho Kim et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines
Cui-rong Zhao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma
Ahmed Alasker et al.
CANCER TREATMENT REVIEWS (2013)
Fibroblast growth factor receptors, developmental corruption and malignant disease
Fergal C. Kelleher et al.
CARCINOGENESIS (2013)
The Discovery of PLK4 Inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents
Radoslaw Laufer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Indazole-Based Potent and Cell-Active Mps1 Kinase Inhibitors: Rational Design from Pan-Kinase Inhibitor Anthrapyrazolone (SP600125)
Ken-ichi Kusakabe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors
Rand M. Miller et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
Chemistry and Biology of Indoles and Indazoles: A Mini-Review
Nasir Shafakat Ali et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2013)
Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
Hideki Terai et al.
MOLECULAR CANCER RESEARCH (2013)
Development of PI3K inhibitors: lessons learned from early clinical trials
Jordi Rodon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
EGFR inhibition in non-small cell lung cancer: current evidence and future directions
Alexander Chi et al.
BIOMARKER RESEARCH (2013)
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Paul R. Gavine et al.
CANCER RESEARCH (2012)
Osmium(IV) complexes with 1H- and 2H-indazoles: Tautomer identity versus spectroscopic properties and antiproliferative activity
Gabriel E. Buechel et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
Basic and Therapeutic Aspects of Angiogenesis
Michael Potente et al.
CELL (2011)
Estrogen Receptors: Therapies Targeted to Receptor Subtypes
S. Nilsson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Dysregulation of CDK8 and Cyclin C in tumorigenesis
Wu Xu et al.
JOURNAL OF GENETICS AND GENOMICS (2011)
Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
Vito Guagnano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells
Jewel Daniel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
1-[(Imidazolidin-2-yl)imino]indazole.: Highly α2/I1 selective agonist:: Synthesis, X-ray structure, and biological activity
Franciszek Saczewski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Ron Firestein et al.
NATURE (2008)
N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck:: Indazoles as phenol isosteres with improved pharmacokinetics
Paul Bamborough et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Exploring the specificity of the PI3K family inhibitor LY294002
Severine I. Gharbi et al.
BIOCHEMICAL JOURNAL (2007)
Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases
Christopher M. McBride et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Pharmacological properties of indazole derivatives:: Recent developments
H Cerecetto et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2005)
Cellular signaling by fibroblast growth factor receptors
VP Eswarakumar et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
PDK1, the master regulator of AGC kinase signal transduction
A Mora et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2004)
Somatic mutations of EGFR in colorectal cancers and glioblastomas
TD Barber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Tyrosine kinase inhibitors in cancer therapy
S Madhusudan et al.
CLINICAL BIOCHEMISTRY (2004)
Structure-based design, synthesis, and antimicrobial activity of indazole-derived SAH/MTA nucleosidase inhibitors
XM Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
J Mendelsohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
SS Sridhar et al.
LANCET ONCOLOGY (2003)
Share Paper
